KIGALI, Rwanda and ADDIS ABABA, Ethiopia -- During the COECSA Congress, Bio Usawa’s leadership team paid a courtesy visit to the Director General of the Ethiopian Food and Drug Authority (EFDA), Ms. Heran Gerba, at the Authority’s headquarters in Addis Ababa.

The team expressed gratitude to Ms. Gerba and her staff for their warm reception. Bio Usawa’s COO, Dr. Patrick Lukulay, also renewed a professional acquaintance with the Director General, having collaborated with her over 15 years ago during his leadership of the USAID-funded PQM program to strengthen regulatory systems in low- and middle-income countries.

In the meeting, the Bio Usawa team outlined the company’s mission to advance health sovereignty in Africa through local manufacturing of monoclonal antibodies targeting infectious diseases, cancer, and diabetic eye diseases. The discussion highlighted the critical role of Bio Usawa’s biologics in saving lives — medicines made in Africa, for genomically appropriate African patients, by Africans. This mission aligns closely with EFDA’s vision to ensure access to safe, effective, and quality-assured medicines for all.

About Bio Usawa, Inc.

Bio Usawa is Rwanda's leading biotechnology company dedicated to democratizing access to life-saving biopharmaceuticals across Africa. Founded on the principle that geographic location should not determine healthcare outcomes, the company specializes in developing and manufacturing affordable, high-quality monoclonal antibodies targeting cancer, diabetes complications, infectious diseases, and autoimmune conditions. Bio Usawa's leadership team brings decades of experience from leading global biotech companies and international regulatory agencies.